9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 201–300 of 773
Association between exenatide use and incidence of Alzheimer's disease
Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D. P., & Romley, J. A. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12139 · Cited by 33
Sameeh, M. Y., Khowdiary, M. M., Nassar, H. S., Abdelall, M. M., Amer, H. H., Hamed, A., & Elhenawy, A. A. (2022) · Molecules · doi:10.3390/molecules27030830 · Cited by 31
Lin, B., Ma, Y., & Jun-wei, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.870049 · Cited by 29
“Prodrugs modified with amino acids, folate, and sugar moieties have the potential to be used for renal targeting (Association, 2019b).”
BackgroundInfluentialMetabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
Zhang, W., Li, X., Ding, H., Lu, Y., Stilwell, G., Halvorsen, Y. C., & Welihinda, A. A. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1654634 · Cited by 29
Moon, S., Kim, C. H., Kang, S. M., Kim, E. S., Oh, T. J., Yun, J., Cho, H., Kim, D. J., & Park, T. S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0120 · Cited by 29
Gunawan, F., Nassif, M. E., Partridge, C., Ahmad, T., Kosiborod, M., & Inzucchi, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000195 · Cited by 28
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Łojko, D., Owecki, M., & Suwalska, A. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16071132 · Cited by 30
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Diabetes mellitus and its many complications
Reddy, S. S. K., & Tan, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820605-8.00001-2 · Cited by 36
Al‐Saleh, Y., Sabico, S., Al-Furqani, A., Jayyousi, A., Alromaihi, D., Ba-Essa, E. M., Alawadi, F., Alkaabi, J., Hassanein, M. M., Alsifri, S. N., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01059-1 · Cited by 36
Inoue, K., Tsugawa, Y., Mangione, C. M., & Duru, O. K. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003645 · Cited by 27
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 28
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 31
Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus
Canpolat, A. G., & Şahin, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_516 · Cited by 29
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
Anderson, S., Cotiguala, L., Tischer, S. M., Park, J. M., & McMurry, K. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020951955 · Cited by 28
McKee, A. M., Al-Khazaali, A., & Albert, S. G. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa037 · Cited by 27
Management of cardiovascular disease in patients with systemic lupus erythematosus
Piranavan, P., & Perl, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770227 · Cited by 27
Gebrie, D., Manyazewal, T., Ejigu, D. A., & Makonnen, E. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312997 · Cited by 28
Hunt, B., Hansen, B. B., Ericsson, Å., Kallenbach, K., Ali, S. N., Dang‐Tan, T., Malkin, S. J. P., & Valentine, W. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01125-y · Cited by 28
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Erythropoulou-Kaltsidou, A., Polychronopoulos, G., & Τζιόμαλος, Κ. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00724-w · Cited by 26
Hung, C., Liu, J., Cheng, C., Chung, C., Chiang, C., Chien, W., & Wang, W. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15195 · Cited by 26
Neuen, B. L., Jardine, M., & Perkovic, V. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz252 · Cited by 28
Lane, W. S., Favaro, E., Rathor, N., Jang, H. C., Kjaersgaard, M. I. S., Oviedo, A., Rose, L., Senior, P. A., Sesti, G., Gonzalez, A. S., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2232 · Cited by 26
Persson, S., Johansen, P., Andersson, E., Lindgren, P., Thielke, D., Thorsted, B. L., JENDLE, J. H., & Carlsson, K. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14070 · Cited by 30
Kim, S. H., Park, T. S., & Jin, H. Y. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0190 · Cited by 26
The Need for Precision Medicine to be Applied to Diabetes
Klonoff, D. C., Florez, J. C., German, M. S., & Fleming, A. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819894295 · Cited by 26
BAJAJ, H. S., Raz, I., Mosenzon, O., Murphy, S. A., Rozenberg, A., Yanuv, I., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14011 · Cited by 27
Guzauskas, G. F., Rind, D. M., Fazioli, K., Chapman, R. H., Pearson, S. D., & Hansen, R. N. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.4.455 · Cited by 25
Yagi, N., Komiya, I., Arai, K., Oishi, M., Fukumoto, Y., Shirabe, S., Yokoyama, H., Yamazaki, K., Sugimoto, H., & Maegawa, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13621 · Cited by 28
Korayem, G. B., Alshaya, O. A., Alghamdi, A. A., ALANAZI, S., Almutib, R. T., Alsaileek, M., Alrashidi, A., Aldosari, N., Sheraim, N. B., Yami, M. S. A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1031306 · Cited by 26
Myopathy secondary to empagliflozin therapy in type 2 diabetes
Gao, F., Hall, S., & Bach, L. A. (2020) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0017 · Cited by 25
Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
Oyagüez, I., Peralta, F. G., Artola, S., Carrasco-Sánchez, F. J., Carretero‐Gómez, J., Soidán, F. J. G., Gómez‐Huelgas, R., Merino-Torres, J. F., & Pérez, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01064-4 · Cited by 25
Approaches to risk assessment among older patients with diabetes
Pilla, S. J., Schoenborn, N. L., Maruthur, N. M., & Huang, E. S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1172-z · Cited by 24
Dixon, D. L., Salgado, T. M., Robinson, A., Carbone, S., Wagner, T. D., Hyder, H., Kirschner, B., Musselman, K. T., Buffington, T. M., & Sabo, R. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.026 · Cited by 25
Gu, S., Shi, L., Shao, H., Wang, X., Hu, X., Gu, Y., & Dong, H. (2020) · BMC Medicine · doi:10.1186/s12916-020-01837-x · Cited by 24
Diabetes: how to manage patients experiencing hypoglycaemia
Lowe, R. N., Williams, B., & Claus, L. W. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-11 · Cited by 27
Lim, J., Hwang, I., Choi, H., Yoon, Y. E., & Cho, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269414 · Cited by 26
Management of Diabetes in Patients Undergoing Bariatric Surgery
Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 27
Özçelik, S., Çelik, M., Vural, A., Aydın, B., Özçelik, M., & Gözü, H. I. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.93264 · Cited by 24
Petchsila, K., Prueksaritanond, N., Insin, P., Yanaranop, M., & Chotikawichean, N. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.3.733 · Cited by 24
Gilstrap, L. G., Blair, R. A., Huskamp, H. A., Zelevinsky, K., & Normand, S. T. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5411 · Cited by 24
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
Pucelik, B., Barzowska, A., Dąbrowski, J. M., & Czarna, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169083 · Cited by 23
Brunetti, V. C., Reynier, P., Azoulay, L., Yu, O. H. Y., Ernst, P., Platt, R. W., & Filion, K. B. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5192 · Cited by 24
Giugliano, D., Ceriello, A., De Nicola, L., Perrone‐Filardi, P., Cosentino, F., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13881 · Cited by 22
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes
O’Keefe, J. H., Nassif, M. E., MAGWIRE, M. L., O’Keefe, E. L., & Lavie, C. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.001 · Cited by 22
Inagaki, N., Yang, W., Watada, H., Ji, L., Schnaidt, S., Pfarr, E., Okamura, T., Johansen, O. E., George, J. T., von Eynatten, M., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00412-x · Cited by 22
Rikin, S., Deccy, S., Zhang, C., Crandall, J. P., Deng, Y., & Golestaneh, L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07863-0 · Cited by 22
Parigi, A. D., Tang, W., Liu, D., Lee, C. S., & Pratley, R. E. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00281-4 · Cited by 29
Triantafylidis, L. K., Hawley, C. E., Fagbote, C. O., Li, J., Genovese, N., & Paik, J. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019876499 · Cited by 22
Dorcely, B., Nitis, J., Schwartzbard, A. Z., Newman, J. D., Goldberg, I. J., & Sum, M. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200316112709 · Cited by 24
Mordi, I. R., Tee, A., Palmer, C. N., McCrimmon, R. J., Doney, A. S. F., & Lang, C. C. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12669 · Cited by 23
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Medicaid Expansion and Utilization of Antihyperglycemic Therapies
Sumarsono, A., Buckley, L. F., Machado, S., Wadhera, R. K., Warraich, H. J., Desai, R. J., Everett, B. M., McGuire, D. K., Fonarow, G. C., Butler, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0735 · Cited by 23
Tay, J., Thompson, C. H., Luscombe‐Marsh, N. D., Noakes, M., Buckley, J. D., Wittert, G., & Brinkworth, G. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108501 · Cited by 23
You, J. H., Song, S. O., Kang, M. J., Cho, Y. Y., Kim, S. W., Suh, S. H., Lee, S., Lee, Y., & Lee, B. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000254 · Cited by 22
Demir, T., Turan, S., Ünlühızarcı, K., Topaloğlu, O., Tükek, T., & Yavuz, D. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.616514 · Cited by 22
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Sumarsono, A., Everett, B. M., McGuire, D. K., Fonarow, G. C., Butler, J., Pandey, A., & Vaduganathan, M. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.3884 · Cited by 21
Mendez, C. E., Walker, R. J., Eiler, C., Mishriky, B. M., & Egede, L. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1643635 · Cited by 21
Kitten, A., Kamath, M., Ryan, L., & Reveles, K. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221174 · Cited by 21
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 23
Harris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Molina-Güarneros, J., Sáinz-Gil, M., Fadrique, R. S., García, P. O., Rodríguez‐Jiménez, P., Navarro-García, E., & Arias, L. H. M. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01003-6 · Cited by 21
Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kim, K., Choi, Y. K., Kim, M. J., Hwang, J. W., Min, K., Jung, S. Y., Kim, S.-K., Cho, Y.-W., & Cho, Y.-W. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0191 · Cited by 22
Lu, C., Chung, C., Kuo, F.-C., Chen, K.-C., Chang, C., Kuo, C., Lee, C.-H., Su, S., Liu, J., Lin, F., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092839 · Cited by 21
Chen, X., He, X., Guo, Y., Liu, L., Li, H., Tan, J., Feng, W., Guan, H., Cao, X., Xiao, H., et al. (2021) · The FASEB Journal · doi:10.1096/fj.201903253r · Cited by 22
Leonard, C. E., Brensinger, C. M., Dawwas, G. K., Deo, R., Bilker, W. B., Soprano, S. E., Dhopeshwarkar, N., Flory, J., Bloomgarden, Z. T., Gagne, J. J., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00999-5 · Cited by 21
Diabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 22
Chadha, M. D., Jain, S. M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P., Tripathi, S., Singh, S., Gutch, M., & Dasgupta, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230116150205 · Cited by 20
“While according to the recommendations until 2018 [36], advancement to combination injectable therapy was recommended if the basal insulin dose was >0.5 U/kg/day, it was modified to >0.7-1.0 U/kg in the 2019 guidelines [37].”
BackgroundMethodInfluentialSantamarina, M. L., & Carlson, C. J. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1036-0 · Cited by 21
Farngren, J., & Åhrén, B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.016 · Cited by 21
Huang, Y., Cuiping, J., Wen, T., Qiu, J., Xiaoming, T., Qin, G., Haidong, W., Sun, J., & Zhijun, B. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13087 · Cited by 20
Jaidee, R., Kongpetch, S., Senggunprai, L., Prawan, A., Kukongviriyapan, U., & Kukongviriyapan, V. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01885-3 · Cited by 21
Home, P. D., Blonde, L., Kalra, S., Ji, L., Guyot, P., Brulle-Wohlhueter, C., Murray, E. M., Shah, R., Sayre, T., & Shaunik, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14148 · Cited by 22
Luo, J., & Gellad, W. F. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-1286-3 · Cited by 23
Grunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-00173-8 · Cited by 19
Hsia, S. H., Duran, P. A., Lee, M. L., & Davidson, M. B. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12989 · Cited by 21
Hypoglycemia in Older Patients
Hoogwerf, B. J. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.001 · Cited by 20
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
Freemantle, N., Mauricio, D., Giaccari, A., Bailey, T. S., Roussel, R., Franco, D. R., Berthou, B., Pilorget, V., Westerbacka, J., Bosnyák, Z., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1708287 · Cited by 19
Keleş, S., Anık, A., Çevik, Ö. D., Abas, B. İ., & Anık, A. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-020-03238-z · Cited by 19
Katsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 20
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study
Milani, R. V., Chava, P., Wilt, J. K., Entwisle, J., Karam, S., Burton, J. H., & Blonde, L. (2021) · JMIR Diabetes · doi:10.2196/24687 · Cited by 20
Arshad, A., Sarween, N., & Sharif, A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.029 · Cited by 20
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
Schernthaner, G., Karasik, A., Abraitienė, A., As, A., Gaál, Z., Gumprecht, J., Janež, A., Kaser, S., Lalic, K. S., Mankovsky, B., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0920-3 · Cited by 20
Maegawa, H., Ishigaki, Y., Langer, J., Saotome‐Nakamura, A., Andersen, M., & the Japan Diabetes Clinical Data Management (JDDM) Study Group (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13352 · Cited by 18
Sönmez, A., Taşçı, İ., Demirci, İ., Haymana, C., Barçın, C., Aydin, H., Çetinkalp, Ş., Öztürk, F. Y., Gül, K., Sabuncu, T., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00779-0 · Cited by 18
Song, Y., Ku, B. J., Cho, J., Jun, Y., Kim, B., & Nam, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.77 · Cited by 18
Mody, R., Huang, Q., Yu, M. B., Patel, H., Zhang, X., Wang, L., & Grabner, M. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000884 · Cited by 18
Kameda, T., Kumamaru, H., Nishimura, S., Kohsaka, S., & Miyata, H. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729710 · Cited by 18
Kim, J., Hyun, H.-J., Choi, E.-A., Kim, Y., Bae, Y., & Kang, H. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01085-1 · Cited by 18
Egede, L. E., Bogdanov, A., Fischer, L., Fernandes, J. D. D. R., & Kallenbach, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00850-w · Cited by 18
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects
Henriksen, K., Broekhuizen, K., de Boon, W. M. I., Karsdal, M. A., Bihlet, A. R., Christiansen, C., Dillingh, M. R., de Kam, M., Kumar, R., Burggraaf, J., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14921 · Cited by 18
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 20
Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts
Zaharia, O., Lanzinger, S., Rosenbauer, J., Karges, W., Müssig, K., Meyhöfer, S. M., Burkart, V., Hummel, M., Raddatz, D., Roden, M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.760778 · Cited by 17
Chang, L., Vaduganathan, M., Plutzky, J., & Aroda, V. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1260-0 · Cited by 17
Shin, Y., Moon, J. H., Chin, H. J., Ferrannini, E., & Lim, S. K. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.329 · Cited by 19
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.